54 related articles for article (PubMed ID: 2618764)
1. Intraventricular injection of neurotensin reduces the binding of dopamine D-2 receptors in the rat forebrain.
von Euler G; Meister B; Hökfelt T; Fuxe K
Acta Physiol Scand; 1989 Oct; 137(2):309-10. PubMed ID: 2618764
[No Abstract] [Full Text] [Related]
2. Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland. Relationship to serum hormone levels and nerve terminal coexistence.
von Euler G; Meister B; Hökfelt T; Eneroth P; Fuxe K
Brain Res; 1990 Oct; 531(1-2):253-62. PubMed ID: 1981163
[TBL] [Abstract][Full Text] [Related]
3. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
[TBL] [Abstract][Full Text] [Related]
4. Differential labelling of dopamine receptors in rat brain in vivo: comparison of [3H]piribedil, [3H]S 3608 and [3H]N,n-propylnorapomorphine.
Hall MD; Jenner P; Marsden CD
Eur J Pharmacol; 1983 Jan; 87(1):85-94. PubMed ID: 6188621
[No Abstract] [Full Text] [Related]
5. Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes.
Von Euler G; Fuxe K
Acta Physiol Scand; 1987 Dec; 131(4):625-6. PubMed ID: 3442244
[No Abstract] [Full Text] [Related]
6. Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites.
Agnati LF; Fuxe K; Benfenati F; Battistini N
Acta Physiol Scand; 1983 Dec; 119(4):459-61. PubMed ID: 6320589
[No Abstract] [Full Text] [Related]
7. Neurotensin modulates the binding characteristics of dopamine D2 receptors in rat striatal membranes also following treatment with toluene.
von Euler G; Fuxe K; Benfenati F; Hansson T; Agnati LF; Gustafsson JA
Acta Physiol Scand; 1989 Apr; 135(4):443-8. PubMed ID: 2525310
[TBL] [Abstract][Full Text] [Related]
8. Dopamine receptor elevation by cholecystokinin.
Dumbrille-Ross A; Seeman P
Peptides; 1984; 5(6):1207-12. PubMed ID: 6531273
[TBL] [Abstract][Full Text] [Related]
9. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.
Reches A; Burke RE; Kuhn CM; Hassan MN; Jackson VR; Fahn S
J Pharmacol Exp Ther; 1983 Jun; 225(3):515-21. PubMed ID: 6864517
[TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin peptides in vitro modulate the characteristics of the striatal 3H-N-propylnorapomorphine sites.
Agnati LF; Celani MF; Fuxe K
Acta Physiol Scand; 1983 May; 118(1):79-81. PubMed ID: 6312748
[No Abstract] [Full Text] [Related]
11. High affinity dopamine receptors (D3) in rat brain.
Titeler M; List S; Seeman P
Commun Psychopharmacol; 1979; 3(6):411-20. PubMed ID: 546589
[No Abstract] [Full Text] [Related]
12. Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism.
von Euler G; van der Ploeg I; Fredholm BB; Fuxe K
J Neurochem; 1991 Jan; 56(1):178-83. PubMed ID: 1824779
[TBL] [Abstract][Full Text] [Related]
13. Age-related changes in neurotensin content and receptors in various rat brain areas.
Govoni S; Di Giovine S; Battaini F; Trabucchi M
Exp Aging Res; 1986; 12(4):197-201. PubMed ID: 3569395
[TBL] [Abstract][Full Text] [Related]
14. Interactions of a partial ergoline with dopamine receptors in vivo and in vitro.
Fuxe K; Goldstein M; Agnati LF; Köhler C; Lew JY; Okada K
Acta Physiol Scand; 1983 Feb; 117(2):303-5. PubMed ID: 6869037
[No Abstract] [Full Text] [Related]
15. Studies on aging processes.
Agnati LF; Fuxe K; Benfenati F; Toffano G; Cimino M; Battistini N; Calza L; Merlo Pich E
Acta Physiol Scand Suppl; 1984; 532():45-61. PubMed ID: 6093434
[TBL] [Abstract][Full Text] [Related]
16. Rotational behaviour elicited by intracerebral injections of apomorphine and pergolide in 6-hydroxy-dopamine-lesioned rats. II: The striatum of the rat is heterogeneously organized for rotational behaviour.
Herrera-Marschitz M; Forster C; Ungerstedt U
Acta Physiol Scand; 1985 Nov; 125(3):529-35. PubMed ID: 3936339
[TBL] [Abstract][Full Text] [Related]
17. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. II. Involvement of the mesolimbic dopamine system.
Kalivas PW
J Pharmacol Exp Ther; 1985 Nov; 235(2):544-50. PubMed ID: 4057084
[TBL] [Abstract][Full Text] [Related]
18. Effect of methamphetamine on neurotensin concentrations in rat brain regions.
Letter AA; Merchant K; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1987 May; 241(2):443-7. PubMed ID: 3572804
[TBL] [Abstract][Full Text] [Related]
19. Further evidence for the existence of interactions between receptors for dopamine and neurotensin. Dopamine reduces the affinity and increases the number of [3H]-neurotensin binding sites in the subcortical limbic forebrain of the rat.
Agnati LF; Fuxe K; Battistini N; Giardino L; Benfenati F; Martire M; Ruggeri M
Acta Physiol Scand; 1985 May; 124(1):125-8. PubMed ID: 2990164
[No Abstract] [Full Text] [Related]
20. Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain.
Wang R; Boules M; Gollatz E; Williams K; Tiner W; Richelson E
Brain Res Mol Brain Res; 2005 Jul; 138(1):24-34. PubMed ID: 15878217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
